TROPION-Lung01 Study Design and Baseline demographics
Baseline demographics and disease characteristics
Data cutoff: July 14, 2023
Received 4.8-8.0 mg/kg R-DXd
(OVC population; N=60)
Daiichi-Sankyo
OVC
(4.8-8.0 mg/kg)
N=60
4.8 mg/kga
(n=13)
5.6 mg/kga
(n=8)
6.4 mg/kgb
(n=24)
8.0 mg/kg
(n=15)
Age, median years (range)
ECOG PS, n (%)
66 (42-82)
Ongoing
on treatment:
n=9
Ongoing
on treatment:
n=8
Ongoing
on treatment:
n=13
Ongoing
0
22 (36.7)
on treatment:
n=3
1
38 (63.3)
Platinum-resistant diseasee, n (%)
55 (91.7)
Discontinued (n=27)
Number of prior systemic regimens,
median (range)
4 (1-13)
Received prior systemic therapy, n (%)
PD
(n=14)
Clinical progression
(n=2)
TEAE
(n=9)
Otherd
(n=2)
Bevacizumab
41 (68.3)
PARP inhibitor
39 (65.0)
•
Median treatment duration: 18 weeks (range: 3-115)
•
12 (20%) patients received treatment for ≥6 months
•
3 (5%) patients received treatment for ≥18 months
Baseline tumor CDH6 expression H-score,
median (range)
125 (0-250)
"Enrollment ongoing. "Enrollment completed. "As of October 2022, the patients who were still receiving R-DXd at 8.0 mg/kg were dose-reduced to receive R-DXD 6.4 mg/kg. "Death (n=1) and informed consent withdrawn (n=1). "Defined as tumor progression during or within 6 months after completion of
prior platinum therapy. Five patients had tumor progression 6 months after platinum therapy.
CDH8, cadherin 8; ECOG PS, Eastern Cooperative Oncology Group performance status; OVC, ovarian cancer; PARP, poly adenosine diphosphate-ribose polymerase; PD, progressive disease; TEAE, treatment-emergent adverse event.
55View entire presentation